Circulating telopeptide type I is a peripheral marker of thyroid hormone action in hyperthyroidism and during levothyroxine suppressive therapy

Thyroid

Volumn 7, Issue 4, 1997, Pages 561-566

  Loviselli, A ^a   Mastinu, R ^a   Rizzolo, E ^a   Massa, G M ^a   Velluzzi, F ^a   Sammartano, L ^a   Mela, Q ^a   Mariotti, S ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOTHYROXINE; OSTEOCALCIN; SEX HORMONE BINDING GLOBULIN; THYROID HORMONE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; FEMALE; HORMONE ACTION; HORMONE BLOOD LEVEL; HUMAN; HYPERTHYROIDISM; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL;

EID: 0030768442     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.1997.7.561     Document Type: Article

References (27)

1. Escobar-Morreale HF, Del Rey FE, Obregon MJ, Morreale de Escobar G 1996 Only the combined treatment with thyroxine and triiodothyronine ensures euthyroidism in all tissues of the thyroidectomized rat. Endocrinology 137:2490-2502.
2. Chopra I 1996 Nature, source and relative significance of circulating thyroid hormones. In: Braverman LE, Utiger RD (eds) Werner's and Ingbars' The Thyroid. 7th ed. Lippincott-Raven Publishers, Philadelphia, pp 111-124.
3. Refetoff S 1989 Thyroid function tests and effects of drugs on thyroid function. In: De Groot LJ (ed) Endocrinology. 2nd ed. W.B. Saunders Co, Philadelphia, pp 590-639.
4. De Nayer P, Lambot MP, Desmons MC, Rennotte B, Malvaux P, Beckers C 1986 Sex hormone-binding protein in hyperthyroxinemic patients: A discriminator for thyroid status in thyroid hormone resistance and familial dysalbuminemic hyperthyroxinemia. J Clin Endocrinol Metab 62:1309-1312.
5. Bartalena L, Martino E, Pacchiarotti A, Grasso L, Aghini LF, Buratti L, Bambini G, Breccia M, Pinchera A 1987 Factors affecting suppression of endogenous thyrotropin secretion by thyroxine treatment: Retrospective analysis in athyreotic and goitrous patients. J Clin Endocrinol Metab 64:849-855.
6. Bartalena L, Pinchera A 1994 Levothyroxine suppressive therapy: Harmful and useless or harmless and useful? J Endocrinol Invest 17:675-677.
7. Oppenheimer JH, Schwartz HL, Strait KA 1994 Thyroid hormone action 1994: the plot thickens. Eur J Endocrinol 130:15-24.
8. Chin WW 1994 Molecular mechanisms of thyroid hormone action. Thyroid 4:389-393.
9. Oppenheimer JH, Schartz HL, Strait KA 1995 An integrated view of thyroid hormone actions in vivo. In: Weintraub B (ed) Molecular Endocrinology: Basic Concepts and Clinical Correlations. Raven Press Ltd, New York, pp 249-268.
10. Ross DS 1994 Hyperthyroidism, thyroid hormone therapy, and bone. Thyroid 4:319-326.
11. Conti A, Monzani M, Persani L, Sartorio A 1994 Serum levels of the carboxyterminal telopeptide of type I collagen in patients with thyroid disorders. Minerva Endocrinol 19:127-131.
12. Wenisch C, Bankl HC, Schonthal E, Myskiw D, Presterl E, Rumpold H, Graninger W 1995 Serum levels of the carboxyterminal cross-linked telopeptide of type I collagen and laminin are elevated in Graves' disease but not in toxic nodular goiter. Clin Immunol Immunopathol 75:225-230.
13. Garnero P, Vassy V, Bertholin A, Riou JP, Delmas PD 1994 Markers of bone turnover in hyperthyrdoism and the effects of treatment. J Clin Endocrinol Metab 78:955-959.
14. Galen R, Gambino S 1975 Beyond normality: The Predictive Value and Efficiency of Medical Diagnosis. John Wiley, New York.
15. Garrel DR, Delmas PD, Malavai L, Tourniaare J 1986 Serum bone Gla protein: A marker of bone turnover in hyperthyroidism. J Clin Endocrinol Metab 62:1052-1058.
16. Frevert EU, Biester A, Muller MJ, H. S-G, von zur Mühlen A, Brabant G 1994 Markers of bone metabolism during short-term administration of thyroxine in healthy volunteers. Eur J Endocrinol 131:145-149.
17. Taimela E, Taimela S, Nikkanen V, Irjala K 1994 Accelerated bone degradation in thyroid carcinoma patients during thyroxine treatment, measured by determination of the carboxyterminal telopeptide region of type I collagen in serum. Eur J Clin Chem Clin Biochem 32:827-831.
18. Campbell J, Day P, Diamond T1996 Fine adjustments in thyroxine replacement and its effect on bone metabolism. Thyroid 6:75-78.
19. Allain TJ, McGregor AM 1993 Thyroid hormones and bone. J Endocrinol 139:9-18.
20. Roti E, Minelli R, Gardini E, Braverman LE 1993 The use and misuse of thyroid hormone. Endocr Rev 14:377-399.
21. Larsen PR, Silva JE, Kaplan MM 1981 Relationship between circulating and intracellular thyroid hormones: Physiological and clinical implications. Endocr Rev 2:87-102.
22. Toft AD 1991 Thyroxine replacement therapy. Clin Endocrinol (Oxf) 34:103-105.
23. Giagulli VA, Vermeulen A 1992 Increased plasma 5 alpha-androstane-3 alpha, 17 beta-diol glucuronide concentration in clinically euthyroid women with suppressed plasma thyrotropin levels: Further evidence for generalized tissue over-exposure to thyroid hormones in these subjects. J Clin Endocrinol Metab 74:1465-1467.
24. Marcocci C, Golia F, Bruno-Bossio G, Vignali E, Pinchera A 1994 Carefully monitored levothyroxine suppressive therapy is not associated with bone loss in premenopausal women [see comments]. J Clin Endocrinol Metab 78:818-823.
25. Hawkins F, Rigopoulou D, Papapietro K, Lopez MB 1994 Spinal bone mass after long-term treatment with L-thyroxine in postmenopausal women with thyroid cancer and chronic lymphocytic thyroiditis. Calcif Tiss Int 54:16-19.
26. Mcdermott MT, Perloff JJ, Kidd GS 1995 A longitudinal assessment of bone loss in women with levothyroxine-suppressed benign thyroid disease and thyroid cancer. Calcif Tissue Int 56:521-525.
27. Fujiyama K, Kiriyama T, Ito M, Kimura H, Ashizawa K, Tsuruta M, Nagayama Y, Villadolid MC, Yokoyama N, Nagataki S 1995 Suppressive doses of thyroxine do not accelerate age-related bone loss in late postmenopausal women. Thyroid 5:13-17.